Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.50
pages 51-67

Antiangiogenic Therapies Targeting the Vascular Endothelia Growth Factor Signaling System

Jeanne Tie
Royal Melbourne Hospital, Western Hospital, and Ludwig Institute for Cancer Research, Parkville, Victoria, Australia
Jayesh Desai
Royal Melbourne Hospital, Peter McCallum Cancer Center, and Ludwig Institute for Cancer Research, Parkville, Victoria, Australia


Angiogenesis is critical to the growth of human tumors and the development of metastasis. Amongst the many proangiogenic mechanisms identified, the vascular endothelial growth factor (VEGF) signaling pathway has been implicated as the key regulator of tumor neovascularisation. Various therapeutic agents targeting the VEGF pathway have been successfully developed, with many now approved and in routine clinical use. In general, VEGF-mediated angiogenesis can be inhibited by 2 approaches: antibodies directed against VEGF ligands or VEGF receptors (VEGFRs) and tyrosine kinase inhibitors targeting the VEGFRs. Thus far, clinical benefits achieved with VEGF-targeted agents are limited by their modest efficacy and the development of resistance. With no shortage of drugs in development, the lack of well-validated biomarkers to predict for response or resistance to VEGF-directed therapies is now becoming a key factor limiting the further rational development of this class of anticancer agent. This review discusses the biology of VEGF signaling, the clinical efficacy of VEGF-targeting therapies, potential mechanisms of resistance, and emerging predictive biomarkers.

Articles with similar content:

The Tumor Microenvironment: A Target for Combination therapy of Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1-2
Ralph A. Reisfeld
Venoms Can Be a Boon for Cancer Patients
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Sudhir Kumar, Ruchi Jain, Puja Sarkar
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Mark C. Kelley
Novel Approaches for Colon Cancer Prevention by Cyclooxygenase-2 Inhibitors
Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 2
Bandaru S. Reddy, Chinthalapally V. Rao
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Carlos L. Arteaga, Brent N. Rexer